Regeneron Pharmaceuticals' (REGN) Buy Rating Reaffirmed at Citigroup Inc.


's stock had its "buy" rating reaffirmed by research analysts at Citigroup Inc. in a report released on Friday. They currently have a $420.00 target price on the biopharmaceutical company's stock.



from Biotech News